Clareo Health | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) with diagnosis confirmed by histology or cytology or clinically by American Association for the Study of Liver Diseases criteria for participants with cirrhosis.
Barcelona Clinic Liver Cancer (BCLC) Stage B or C.
Child-Pugh A or B7 classification (i.e., total Child-Pugh score of 5, 6, or 7).
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
You may not be if
Prior systemic therapy for HCC.
Symptomatic, untreated, or actively progressing CNS metastases.
